The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

Cancer Biology & Therapy
Laurence BoothPaul Dent

Abstract

Inhibitors of PARP1 are approved therapeutic agents in ovarian carcinomas. We determined whether the novel clinically relevant CHK1 inhibitor SRA737 interacted with PARP1 inhibitors to kill carcinoma cells. In multiple mammary and ovarian cancer lines SRA737 synergized with the PARP1 inhibitors olaparib and niraparib to cause cell death. The [SRA737 + niraparib] drug combination activated an ATM-AMPK-ULK1-mTOR pathway which resulted in the formation of autophagosomes, temporally followed by autolysosome formation. Phosphorylation of ULK1 S317 was essential for kinase activation against ATG13. The drug combination elevated eIF2α phosphorylation which was causal at increasing Beclin1 and ATG5 expression, reducing MCL-1 and BCL-XL levels, and causing CD95 activation. Knock down of CD95, eIF2α, ATM, AMPKα, ULK1, Beclin1 or ATG5 reduced drug combination lethality. Blockade of either caspase 9 function or that of AIF each partially prevented cell death. Expression of activated mTOR or of c-FLIP-s or of BCL-XL reduced cell killing. In vivo, SRA737 and niraparib interacted in an additive fashion to suppress the growth of mammary tumors. Multiplex analyses revealed that drug combination treated tumors had reduced their plasma levels of ...Continue Reading

References

Nov 16, 2011·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Petra Langerak, Paul Russell
Jun 5, 2012·Frontiers of Medicine·Zhifeng WangCaixia Guo
Mar 5, 2016·Current Treatment Options in Oncology·Fong W Liu, Krishnansu S Tewari
Jun 17, 2016·Molecular & Cellular Oncology·Gwenola ManicIlio Vitale
Nov 29, 2016·Free Radical Biology & Medicine·Rachel Abbotts, David M Wilson
Mar 17, 2017·Expert Opinion on Pharmacotherapy·Yada KanjanapanAmit M Oza
Apr 5, 2017·Journal of the National Cancer Institute·Kelly Y KimBarbara A Conley
Apr 15, 2017·Frontiers in Bioscience (Scholar Edition)·Jyotika RajawatDurga Prasad Mishra
Jun 18, 2017·Molecular Cell·Andrew N Blackford, Stephen P Jackson
Nov 16, 2017·Oncotarget·Laurence BoothPaul Dent

❮ Previous
Next ❯

Citations

Dec 1, 2019·Expert Opinion on Investigational Drugs·Paul Dent
Jun 9, 2020·Expert Reviews in Molecular Medicine·Hannah L SmithNicola J Curtin
May 2, 2020·Signal Transduction and Targeted Therapy·Rui-Xue Huang, Ping-Kun Zhou
Dec 18, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hye-Yon ChoJae Hong No
Jun 3, 2021·International Journal of Molecular Sciences·Hannah E NeigerYihui Shi
Nov 14, 2021·Oncogene·Xiaoning WuValentine M Macaulay

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection

Clinical Trials Mentioned

NCT02797964
NCT02797977

Software Mentioned

Calcusyn
Adobe Photoshop

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Autophagosome

An autophagosome is the formation of double-membrane vesicles that involve numerous proteins and cytoplasmic components. These double-membrane vesicles are then terminated at the lysosome where they are degraded. Discover the latest research on autophagosomes here.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Autophagosome

An autophagosome is the formation of double-membrane vesicles that involve numerous proteins and cytoplasmic components. These double-membrane vesicles are then terminated at the lysosome where they are degraded. Discover the latest research on autophagosomes here.